



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

11 April 2019

Imagion Biosystems receives order related to cancer treatment

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, has announced that NewPhase Ltd., an Israeli biotechnology company developing cancer treatments, has issued an extended purchase order to Imagion Biosystems for the supply of nanoparticles for the remainder of 2019 to be used in the NewPhase product.

NewPhase is developing a proprietary cancer therapy based on hyperthermia, the principle of killing cancer cells by heating them. NewPhase's treatment approach incorporates the use of Imagion Biosystems' iron oxide nanoparticles into a nanoparticle matrix that targets cancerous tumors. When exposed to radio frequency (RF) energy which is harmless to the body, the particles absorb the energy and generate heat, destroying the cancer cell membranes by sub ablative hyperthermia - thus killing cancer cells, and only cancer cells.

"We have been utilizing Imagion Biosystems' nanoparticles in our product development for a couple of years," said Ofer Shalev, Founder and CEO of NewPhase Ltd. "We hope to establish a strong relationship with Imagion to use their nanoparticles in our hyperthermia therapeutic platform as we ramp up our pre-clinical testing and move towards human clinical trials."

"Given our recent announcement that our patent position has been extended to include treatment of disease, we are excited to be working with NewPhase and be part of their product development," said Bob Proulx, Executive Chairman. "While we remain focused on developing our proprietary early cancer detection platform, our work with NewPhase shows we have significant opportunities to monetize our underlying technology for both the detection and treatment of disease."

Imagion Biosystems' current focus on diagnostic imaging addresses a \$2 billion market worldwide. Adding therapeutic utility would expand the revenue opportunity for the company's nanoparticle technologies to the growing market for hyperthermia-based cancer treatments, as well as cancer therapy markets reported to be as much as \$136 billion. While the overall cancer therapy market is forecast to grow at CAGR 8.37% through 2024, the target-therapy segment, which includes toxin delivery vehicles, is expected to show a higher CAGR of 9.68% in the forecast period. This is driven by growing interest and opportunities in the development of precision medicines such as cancer treatments that target the tumor and spare healthy tissue.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420

Imagion Biosystems Limited

ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com